Elekta names members of nomination committee for 2019 AGM.
M2 EQUITYBITES-November 16, 2018-Elekta names members of nomination committee for 2019 AGM
(C)2018 M2 COMMUNICATIONS http://www.m2.com
Human care company Elekta AB (STO:EKTAB) announced on Thursday that the members of its nomination committee, for the 2019 Annual General Meeting, are Laurent Leksell, in his capacity as chairman of the board of directors of Elekta and representing his own and related parties' holdings; Per Colleen, appointed by the Fourth Swedish National Pension Fund; Pontus Dackmo, appointed by Nordea Investment Funds; Tomas Floden, appointed by AMF and AMF Funds and Caroline Sjosten, appointed by Swedbank Robur Funds.
This nomination committee will appoint one of its members as chairman.
Reportedly, in accordance with the resolution passed by Elekta's Annual General Meeting on 30 August 2018, the chairman of the company's board of directors has summoned a nomination committee prior to the 2019 annual general meeting by contacting the company's four largest shareholders in terms of votes, in addition to the shareholder or shareholders represented by the chairman himself.
This nomination committee will present proposals for resolutions by the 2019 Annual General Meeting of Shareholders in relation to chairman of the Annual General Meeting of Shareholders; chairman of the board of directors and other members of the board of directors; fees to the board of directors broken down into amounts for the chairman of the board of directors, other members of the board of directors and members of the board of directors' committees; external auditor and fees to the auditor and where deemed necessary, proposal to amend the procedure for the nomination committee.
Elekta's 2019 Annual General Meeting will take place in Stockholm on 22 August 2019.
Elekta is a provider of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. It offers treatment solutions and oncology informatics portfolios that are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, as well as to drive cost efficiency in clinical workflows.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 16, 2018|
|Previous Article:||GDL Fund declares evaluation of potential alternatives over next weeks.|
|Next Article:||Adams Natural Resources Fund announces distribution of USD0.87 per share for year-end.|